Skip to search formSkip to main contentSkip to account menu

Cytogen 356

Known as: CYT 356, CYT-356 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Capromab Pendetide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.
Highly Cited
1997
Highly Cited
1997
Comparison of serum PSMA, PSA levels with results of cytogen‐356 ProstaScint® scanning in prostatic cancer patients
Stored serum from clinical trial cases undergoing ProstaScint® (CYT‐356) scanning were available for Prostate Specific Membrane… 
Highly Cited
1996
Highly Cited
1996
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
  • N. Deb, M. Goris, S. Knox
  • Clinical cancer research : an official journal of…
  • 1996
  • Corpus ID: 23105335
A Phase I dose-escalation study using 90Y-CYT-356 monoclonal antibody was performed in 12 patients with hormone-refractory… 
Highly Cited
1996
Highly Cited
1996
Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation.
The utility of monoclonal antibody (MAb) imaging for detection of occult recurrent prostate cancer was investigated in 14… 
Highly Cited
1995
Highly Cited
1995
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.
Highly Cited
1995
Highly Cited
1995
Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen.
Highly Cited
1994
Highly Cited
1994
Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
Highly Cited
1994
Highly Cited
1994
Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356.
Highly Cited
1991
Highly Cited
1991
Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)
A phase 1 study was conducted with the investigational immunoscintigraphic agent, 111In‐CYT‐356, a radiolabeled, site‐specific… 
Highly Cited
1990
Highly Cited
1990
Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
In this study, a site-specific immunoconjugate, designated CYT-356, of the prostate-reactive monoclonal antibody 7E11-C5 was… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License